Breast Cancer

Two agents prevent cardiotoxicity in treatment for HER2-positive breast cancer

Cardiotoxicity can be reduced in women with HER2-positive breast cancer being treated with doxyrubicin and trastuzumab (Herceptin) through the use of ACE inhibitors or beta blockers. The findings, presented at the American College of Cardiology’s 67th Annual Scientific Session in Orlando, showed lower cardiac event rates with ACE inhibitors (37%) and beta-blockers (31%) compared to ...

Already a member?

Login to keep reading.

© 2022 the limbic